{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:51:17Z","timestamp":1742388677240},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T00:00:00Z","timestamp":1286236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T00:00:00Z","timestamp":1286236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10637-010-9555-7","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T06:47:21Z","timestamp":1286174841000},"page":"408-416","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Jae-Heon","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Youn","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Hae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Sung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngmee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Lan","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Ho","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seeyoun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungsil","family":"Ro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,5]]},"reference":[{"key":"9555_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10549-007-9672-y","volume":"109","author":"KS Lee","year":"2008","unstructured":"Lee KS, Ro J, Nam B et al (2008) A randomized phase-III trial of docetaxel\/capecitabine versus doxorubicin\/cyclophosphamide as primary chemotherapy for patients with stage II\/III breast cancer. Breast Cancer Res Treat 109:481\u2013489","journal-title":"Breast Cancer Res Treat"},{"key":"9555_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9229-5","author":"KS Lee","year":"2009","unstructured":"Lee KS, Ro J, Lee ES, Kang HS, Kim SW, Nam BH, Kwon Y, Kim EA, Shin KH (2009) Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. Invest New Drugs. doi:10.1007\/s10637-009-9229-5","journal-title":"Invest New Drugs"},{"key":"9555_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"9555_CR4","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging manual","author":"FL Greene","year":"2002","unstructured":"Greene FL, Page DL, Flemming ID (2002) AJCC cancer staging manual, 6th edn. Springer, New York","edition":"6"},{"key":"9555_CR5","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D","volume":"68","author":"DE Henson","year":"1991","unstructured":"Henson DE, Ries L, Freedman LS, Carriaga M (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 68:2142\u20132149","journal-title":"Cancer"},{"key":"9555_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9555_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00253147","volume":"1","author":"M De Lena","year":"1978","unstructured":"De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1:53\u201359","journal-title":"Cancer Chemother Pharmacol"},{"key":"9555_CR8","doi-asserted-by":"crossref","unstructured":"Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr:96\u2013102","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469"},{"key":"9555_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/ejso.2002.1404","volume":"29","author":"VF Cocquyt","year":"2003","unstructured":"Cocquyt VF, Blondeel PN, Depypere HT et al (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29:361\u2013367","journal-title":"Eur J Surg Oncol"},{"key":"9555_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ejca.2003.08.015","volume":"40","author":"MC Mathieu","year":"2004","unstructured":"Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40:342\u2013351","journal-title":"Eur J Cancer"},{"key":"9555_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Gonzalez-Angulo A, Sneige N et al (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41\u201348","journal-title":"J Clin Oncol"},{"key":"9555_CR12","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678\u20135685. doi:10.1158\/1078-0432.CCR-04-2421","journal-title":"Clin Cancer Res"},{"key":"9555_CR13","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019\u20132027. doi:10.1200\/JCO.2005.04.1665","journal-title":"J Clin Oncol"},{"key":"9555_CR14","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1158\/1078-0432.CCR-05-0539","volume":"11","author":"L Gianni","year":"2005","unstructured":"Gianni L, Baselga J, Eiermann W et al (2005) Feasibility and tolerability of sequential doxorubicin\/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715\u20138721. doi:10.1158\/1078-0432.CCR-05-0539","journal-title":"Clin Cancer Res"},{"key":"9555_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037\u20131044. doi:10.1200\/JCO.2005.02.6914","journal-title":"J Clin Oncol"},{"key":"9555_CR16","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","volume":"91","author":"AE Ring","year":"2004","unstructured":"Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91:2012\u20132017. doi:10.1038\/sj.bjc.6602235","journal-title":"Br J Cancer"},{"key":"9555_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/annonc\/mdi001","volume":"16","author":"G von Minckwitz","year":"2005","unstructured":"von Minckwitz G, Blohmer JU, Raab G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56\u201363. doi:10.1093\/annonc\/mdi001","journal-title":"Ann Oncol"},{"key":"9555_CR18","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","volume":"23","author":"G von Minckwitz","year":"2005","unstructured":"von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21\u00a0days compared with doxorubicin and docetaxel every 14\u00a0days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676\u20132685. doi:10.1200\/JCO.2005.05.078","journal-title":"J Clin Oncol"},{"key":"9555_CR19","first-page":"4615","volume":"25","author":"H Prisack","year":"2005","unstructured":"Prisack H, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H (2005) Predictive biological markers for response of invasive breast cancer to anthracycline\/cyclophosphamide-based primary (radio-)chemotherapy. Anticancer Res 25:4615\u20134621","journal-title":"Anticancer Res"},{"key":"9555_CR20","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.2009.25.3286","volume":"28","author":"AS Caudle","year":"2010","unstructured":"Caudle AS, Gonzalez-Angulo AM, Hunt KK et al (2010) Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:1821\u20131828. doi:10.1200\/jco.2009.25.3286","journal-title":"J Clin Oncol"},{"key":"9555_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.23544","volume":"113","author":"F Cuppone","year":"2008","unstructured":"Cuppone F, Bria E, Carlini P et al (2008) Taxanes as primary chemotherapy for early breast cancer. Cancer 113:238\u2013246","journal-title":"Cancer"},{"key":"9555_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/jso.21110","volume":"98","author":"SS Ko","year":"2008","unstructured":"Ko SS (2008) Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10\u00a0years (1996\u20132006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 98:318\u2013323","journal-title":"J Surg Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9555-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9555-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:09:44Z","timestamp":1678511384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9555-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["9555"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9555-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,5]]},"assertion":[{"value":"30 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}